Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TOPLINE
Most Recent Events
- 18 Nov 2024 Status changed from not yet recruiting to recruiting.
- 23 Feb 2024 New trial record